Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Loop Genomics, Integrated DNA Technologies, Dovetail Genomics

Loop Genomics LoopSeq Bacterial Genome Sequencing Kit and Services
Loop Genomics has launched its LoopSeq Bacterial Genome Sequencing Kit and Service for de novo bacterial genome assembly using synthetic long reads on Illumina sequencers. The kit uses the firm's chemistry and computational pipeline to create reads thousands of base pairs long, providing high-quality assemblies with fewer total contigs, higher N50 values, and fewer misassemblies. The San Jose, California-based firm said the kit is plug-and-play and can easily replace existing sample preparation kits for bacterial genome sequencing experiments, using Loop's software for data analysis.

Integrated DNA Technologies oPools Oligo Pools

Integrated DNA Technologies has launched its oPools Oligo Pools, ready-to-use pools of high-quality DNA oligonucleotides. According to the Coralville, Iowa-based firm, the pools contain customized, single-stranded DNA sequences between 40 and 350 nucleotides in length. Because the pools are delivered in picomoles, researchers do not need to perform any pre-amplification or other pre-work before using the pool. IDT said that oPools' low error rate of less than 1 in 2,000 nucleotides, coupled with high per-oligo yields, allow researchers to immediately proceed into their downstream workflows including CRIPSR library construction, protein screening, and gene assembly.

Dovetail Genomics Omni-C Assay

Dovetail Genomics has launched its Omni-C assay, based on the Hi-C method for chromosome conformation capture.
The Scotts Valley, California-based firm said it designed the assay for ease of use and improved reproducibility. The firm claims the assay offers better coverage compared to standard Hi-C approaches by using an endonuclease — rather than restriction enzymes — to digest cross-linked chromatin. Omni-C allows coverage of a significant portion of the genome that does not contain these restriction sites, which is estimated to be around 20 percent in human genomes. The firm believes that applications for Omni-C include structural genetic variant detection and generating genome assemblies.

For more new products and services, please visit the New Products page on our website